Table 2.
Enrichment analysis of genes differentially spliced in IUGR
| Gene set | Description | Expect | Ratio | p value | FDR |
|---|---|---|---|---|---|
| Gene ontology biological processes | |||||
| GO: 0,046,903 | Secretion | 33.803 | 1.8638 | 8.58E–07 | 0.006826 |
| GO: 0,009,628 | Response to abiotic stimulus | 23.651 | 2.0295 | 2.16E–06 | 0.006826 |
| GO: 0,032,940 | Secretion by cell | 31.002 | 1.8709 | 2.25E–06 | 0.006826 |
| GO: 0,045,055 | Regulated exocytosis | 16.491 | 2.1831 | 9.5E–06 | 0.017593 |
| GO: 0,071,363 | Cellular response to growth factor stimulus | 13.9 | 2.3021 | 1.07E–05 | 0.017593 |
| GO: 0,009,719 | Response to endogenous stimulus | 33.592 | 1.7564 | 1.28E–05 | 0.017593 |
| GO: 0,009,725 | Response to hormone | 20.261 | 2.0236 | 1.37E–05 | 0.017593 |
| GO: 0,002,576 | Platelet degranulation | 2.6747 | 4.4864 | 1.55E–05 | 0.017593 |
| GO: 0,006,820 | Anion transport | 12.321 | 2.3538 | 1.86E–05 | 0.018812 |
| GO: 0,070,848 | Response to growth factor | 14.532 | 2.202 | 2.57E–05 | 0.023392 |
| KEGG pathways | |||||
| hsa04913 | Ovarian steroidogenesis | 1.1546 | 6.9286 | 1.6E–05 | 0.003405 |
| hsa04066 | HIF-1 signaling pathway | 2.3564 | 4.6681 | 2.09E–05 | 0.003405 |
| hsa04923 | Regulation of lipolysis in adipocytes | 1.2725 | 5.5012 | 0.000249 | 0.027062 |
| hsa04014 | Ras signaling pathway | 5.4669 | 2.7438 | 0.000359 | 0.029234 |
| Reactome pathways | |||||
| R-HSA-114608 | Platelet degranulation | 3.1046 | 3.8652 | 6.28E–05 | 0.048135 |
| R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ | 3.2249 | 3.721 | 9.1E–05 | 0.048135 |
| R-HSA-202733 | Cell surface interactions at the vascular wall | 3.2971 | 3.6395 | 0.000113 | 0.048135 |
| R-HSA-879518 | Transport of organic anions | 0.2888 | 13.85 | 0.000139 | 0.048135 |
| R-HSA-209822 | Glycoprotein hormones | 0.2888 | 13.85 | 0.000139 | 0.048135 |
| Disease_GLAD4U | |||||
| PA445403 | Pregnancy complications | 5.0666 | 5.5264 | 2.53E–13 | 3.80E–10 |
| PA166048714 | Pregnancy | 6.7088 | 4.7698 | 2.79E–13 | 3.80E–10 |
| PA165108364 | Gestational hypertension | 2.9875 | 6.3598 | 1.73E–10 | 1.57E–07 |
| PA445398 | Pre-Eclampsia | 2.8128 | 5.6882 | 2.44E–08 | 1.45E–05 |
| PA443984 | Eclampsia | 2.8303 | 5.6531 | 2.67E–08 | 1.45E–05 |
| PA445058 | Neoplasm metastasis | 11.409 | 2.8049 | 1.67E–07 | 7.58E–05 |
| PA166048749 | Pregnancy third trimester | 1.1531 | 8.6724 | 2.07E–07 | 8.02E–05 |
| PA165108943 | Retained placenta NOS | 0.47171 | 14.839 | 3.08E–07 | 0.000105 |
| PA446021 | Vascular diseases | 8.5782 | 3.0309 | 5.96E–07 | 0.00018 |
| PA166048848 | Menopause | 2.7429 | 5.104 | 7.00E–07 | 0.00019 |
| Disease_OMIM | |||||
| 611,162 | Malaria, susceptibility to malaria, resistance to, included | 0.076176 | 52.51 | 6.48E–07 | 4.28E–05 |
| 152,700 | Systemic lupus erythematosus | 0.035848 | 55.792 | 0.000523 | 0.017249 |
| 609,423 | Human immunodeficiency virus type 1, susceptibility to | 0.067214 | 29.756 | 0.001924 | 0.028948 |
| 601,665 | Obesity, leanness included | 0.067214 | 29.756 | 0.001924 | 0.028948 |
| 415,000 | Spermatogenic failure, y-linked, 2 | 0.071695 | 27.896 | 0.002193 | 0.028948 |